Hangzhou Highlightll Pharmaceutical Co., Ltd
http://www.highlightllpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hangzhou Highlightll Pharmaceutical Co., Ltd
Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases
The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice